Form 4: CONMED Corp Executive Edward A. Clifford Reports Stock Option Grant

Edward A. Clifford, VP Global Manufacturing at CONMED Corp, reports the acquisition of 26,127 stock options.

Summary

• On March 3, 2025, Edward A. Clifford, VP Global Manufacturing at CONMED Corp, reported a transaction.
• Clifford acquired 26,127 stock options with an exercise price of $58.33.
• These options were granted under the company's 2018 Long-Term Incentive Plan and vest in equal amounts over a five-year period.
• Following the transaction, Clifford directly owns 26,127 derivative securities.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the medical device industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, including those in the medical device sector like CONMED.
• Companies such as Stryker, Johnson & Johnson, and Medtronic also utilize stock options as part of their long-term incentive plans for executives.
• The vesting schedule of five years is fairly typical for stock options, encouraging long-term commitment and performance.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to improve company performance.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates